Should I buy or sell Cingulate stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares. View CING analyst ratings or view top-rated stocks .

What is Cingulate's stock price target for 2024?

3 analysts have issued 12 month price objectives for Cingulate's shares. Their CING share price targets range from $70.00 to $70.00. On average, they expect the company's share price to reach $70.00 in the next year. This suggests a possible upside of 815.0% from the stock's current price. View analysts price targets for CING or view top-rated stocks among Wall Street analysts .

How have CING shares performed in 2023?

Cingulate's stock was trading at $20.00 on January 1st, 2023. Since then, CING shares have decreased by 61.8% and is now trading at $7.65. View the best growth stocks for 2023 here .

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024. View our CING earnings forecast .

How were Cingulate's earnings last quarter?

Cingulate Inc. (NASDAQ:CING) released its quarterly earnings results on Monday, November, 13th. The company reported ($6.00) earnings per share for the quarter, missing the consensus estimate of ($4.80) by $1.20.

When did Cingulate's stock split?

Cingulate's stock reverse split on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

(CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

$7.65

-2.17 (-22.10%)

(As of 12/29/2023 ET)

Compare

Today's Range: $7.43
▼
$9.52
50-Day Range: $1.98
▼
$9.84
52-Week Range: $1.90
▼
$38.60

Volume: 2.87 million shs
Average Volume: 4.24 million shs
Market Capitalization: $7.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $70.00

Cingulate MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 815.0% Upside
$70.00 Price Target
Short Interest: Healthy
0.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($23.20) to ($7.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
Cingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $70.00, Cingulate has a forecasted upside of 815.0% from its current price of $7.65.
Amount of Analyst Coverage
Cingulate has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.07% of the float of Cingulate has been sold short.
Short Interest Ratio / Days to Cover
Cingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cingulate has recently decreased by 15.09%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cingulate does not currently pay a dividend.
Dividend Growth
Cingulate does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CING.

3.0

News and Social Media Coverage

News Sentiment
Cingulate has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Cingulate this week, compared to 2 articles on an average week.
Search Interest
15 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.
MarketBeat Follows
5 people have added Cingulate to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cingulate insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.43% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.75% of the stock of Cingulate is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cingulate are expected to grow in the coming year, from ($23.20) to ($7.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cingulate is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cingulate is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cingulate has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cingulate Stock (NASDAQ:CING)

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CING Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CING Stock News Headlines

December 28, 2023 | bizjournals.com

Cingulate receives second delisting warning following nearly entire board's exit

December 28, 2023 | benzinga.com

Crude Oil Down 1%; US Wholesale Inventories Fall In November

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.

December 28, 2023 | msn.com

Why Is Neurology Focused Cingulate Stock Trading Higher Today?

December 28, 2023 | investorplace.com

Why Is Cingulate (CING) Stock Up 160% Today?

December 28, 2023 | msn.com

Cingulate’s stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

December 26, 2023 | msn.com

If You're Lonely During the Holidays, You're Not Alone

December 23, 2023 | msn.com

Laidlaw & Co. Downgrades Cingulate (CING)

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 23, 2023 | americanbankingnews.com

Cingulate (NASDAQ:CING) Lowered to Hold at Laidlaw

December 19, 2023 | msn.com

Maxim Group Downgrades Cingulate (CING)

December 19, 2023 | benzinga.com

Cingulate Stock (NASDAQ:CING), Analyst Ratings, Price Targets, Predictions

December 18, 2023 | realmoney.thestreet.com

Maxim gets more bearish on Cingulate, downgrades shares

December 17, 2023 | msn.com

The holidays and your brain – a neuroscientist explains how to identify and manage your emotions

December 16, 2023 | msn.com

Cingulate (CING) Price Target Increased by 1382.35% to 80.33

December 16, 2023 | uk.movies.yahoo.com

It’s science: Clutter can definitely give you anxiety

December 15, 2023 | msn.com

7 Smart Strategies to Boost Your Brain Health in the New Year, According to a Cognitive Neuroscientist

December 15, 2023 | marketwatch.com

Cingulate CFO Louis G. Van Horn Retiring >CING

December 15, 2023 | marketwatch.com

Cingulate Shares Hit Record Low After Exodus of Officers, Directors

December 1, 2023 | bizjournals.com

KCK pharmaceutical company completes reverse stock split

December 1, 2023 | baystreet.ca

Cingulate Drops in Price on FDA Guidance

December 1, 2023 | marketwatch.com

Cingulate Receives FDA Guidance for CTx-2103 Anxiety Treatment

December 1, 2023 | finance.yahoo.com

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

November 30, 2023 | marketwatch.com

Cingulate Shares Fall to 52-Week Low After Reverse Split

November 28, 2023 | benzinga.com

Cingulate Stock (NASDAQ:CING) Dividends: History, Yield and Dates

November 18, 2023 | markets.businessinsider.com

Cingulate Inc’s Strong Financial Position and Promising ADHD Drug Development Prospects Garner Buy Rating from Maxim Group

November 17, 2023 | msn.com

Consumption of ultra-processed foods linked to depression and reduced brain volume

See More Headlines

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/08/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CING
CUSIP: N/A
CIK: 1862150
Web: www.cingulate.com
Phone: 913-942-2300
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $70.00
High Stock Price Target: $70.00
Low Stock Price Target: $70.00
Potential Upside/Downside: +815.0%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($32.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,680,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,235.83%
Return on Assets: -285.93%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 0.51
Quick Ratio: 0.51

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.87 per share
Price / Book: 1.11

Miscellaneous

Outstanding Shares: 940,000
Free Float: 577,000
Market Cap: $7.19 million
Optionable: Not Optionable
Beta: -0.70

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Shane J. Schaffer Pharm.D. (Age 48)
PharmD, CEO, Principal Financial Officer & Chairman of the Board
Comp: $504.69k
Dr. Laurie A. Myers M.B.A. (Age 66)
Ph.D., Executive VP & COO
Comp: $425k
Dr. Raul R. Silva M.D. (Age 65)
Executive VP & Chief Science Officer
Thomas Dalton
Head of Investor & Public Relations
Dr. Matthew N. Brams M.D. (Age 59)
Executive VP & Chief Medical Officer
Jennifer L. Callahan
Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CING Stock Analysis - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares.
View CING analyst ratings or view top-rated stocks.
What is Cingulate's stock price target for 2024?: 3 analysts have issued 12 month price objectives for Cingulate's shares. Their CING share price targets range from $70.00 to $70.00. On average, they expect the company's share price to reach $70.00 in the next year. This suggests a possible upside of 815.0% from the stock's current price.
View analysts price targets for CING or view top-rated stocks among Wall Street analysts.
How have CING shares performed in 2023?: Cingulate's stock was trading at $20.00 on January 1st, 2023. Since then, CING shares have decreased by 61.8% and is now trading at $7.65.
View the best growth stocks for 2023 here.
When is Cingulate's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our CING earnings forecast.

How were Cingulate's earnings last quarter?: Cingulate Inc. (NASDAQ:CING) released its quarterly earnings results on Monday, November, 13th. The company reported ($6.00) earnings per share for the quarter, missing the consensus estimate of ($4.80) by $1.20.
When did Cingulate's stock split?: Cingulate's stock reverse split on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
When did Cingulate IPO?: (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.
How do I buy shares of Cingulate?: Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CING) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial